In the first quarter of 2023, the FDA will approve the use of MDMA for treating PTSD in Israel. Israel is expected to follow suit. Research indicates that two months following the end of the treatment, 70% of patients exhibit improvement in PTSD symptoms. MDMA helps patients quickly get to deeper, more traumatic, levels which speeds up the treatment period. Despite MDMA’s reputation as a party drug, the treatment conducted for research purposes has been highly supervised. The treatment is also very closely supervised.Read Long Article
